Protalix published a press release with full-year fiscal 2025 financial and business results. Revenues from selling goods were USD 51.8 million, down 2%, driven mainly by lower sales to Chiesi due to a change in average net selling price and inventory quantities. R&D expenses were USD 19.6 million, up 51%, primarily due to preparations for the RELEASE Phase 2 study of PRX-115. Net loss was USD 6.6 million, and cash, cash equivalents and short-term bank deposits were USD 30.3 million. The company said the European Commission approved a 2mg/kg every-4-weeks dosing regimen for Elfabrio in adults with Fabry disease, triggering entitlement to a USD 25 million milestone payment from Chiesi, and it forecast 2026 total revenue of USD 78 million to USD 83 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protalix BioTherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603180650PR_NEWS_USPR_____LN11956) on March 18, 2026, and is solely responsible for the information contained therein.